Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappaB but is related to downregulation of initiator caspases and DR4. (Q40198109)

From Wikidata

Jump to navigation Jump to search

scientific article published on 11 December 2006

Language	Label	Description	Also known as
English	Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappaB but is related to downregulation of initiator caspases and DR4.	scientific article published on 11 December 2006

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappaB but is related to downregulation of initiator caspases and DR4. (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

1 reference

based on heuristic

inferred from title

author name string

Kurbanov BM

1

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Fecker LF

2

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Geilen CC

3

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Sterry W

4

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Eberle J

5

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

language of work or name

0 references

publication date

11 December 2006

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

26

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

23

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

3364-3377

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Targeting death and decoy receptors of the tumour-necrosis factor superfamily

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210134

21 January 2018

Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210134

21 January 2018

Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210134

21 January 2018

CD95/Fas signaling in human melanoma cells: conditional expression of CD95L/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xenotransplants

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210134

21 January 2018

Downregulation of endothelin B receptor in human melanoma cell lines parallel to differentiation genes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210134

21 January 2018

TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210134

21 January 2018

Loss of proapoptotic Bcl-2-related multidomain proteins in primary melanomas is associated with poor prognosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210134

21 January 2018

Apoptosis-based therapies and drug targets

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210134

21 January 2018

The role of NF-kappa B in TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of melanoma cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210134

21 January 2018

5-Aza-2'-deoxycytidine and IFN-gamma cooperate to sensitize for TRAIL-induced apoptosis by upregulating caspase-8.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210134

21 January 2018

Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210134

21 January 2018

Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210134

21 January 2018

Modulation of tumor necrosis factor apoptosis-inducing ligand- induced NF-kappa B activation by inhibition of apical caspases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210134

21 January 2018

Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and -deficient cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210134

21 January 2018

Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210134

21 January 2018

Death receptors and melanoma resistance to apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210134

21 January 2018

Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210134

21 January 2018

The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210134

21 January 2018

Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210134

21 January 2018

NF-kappaB: linking inflammation and immunity to cancer development and progression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210134

21 January 2018

NF-kappaB at the crossroads of life and death

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210134

21 January 2018

Targeting death receptors in cancer with Apo2L/TRAIL.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210134

21 January 2018

Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210134

21 January 2018

Efficient TRAIL-R1/DR4-mediated apoptosis in melanoma cells by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210134

21 January 2018

Apo2L/TRAIL and its death and decoy receptors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210134

21 January 2018

Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210134

21 January 2018

TRAIL-induced apoptosis and gene induction in HaCaT keratinocytes: differential contribution of TRAIL receptors 1 and 2.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210134

21 January 2018

Proteasome inhibition results in TRAIL sensitization of primary keratinocytes by removing the resistance-mediating block of effector caspase maturation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210134

21 January 2018

Function and regulation of the CD95 (APO-1/Fas) ligand in the immune system

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210134

21 January 2018

TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210134

21 January 2018

NF-kappaB in cancer--a friend turned foe.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210134

21 January 2018

Type I and type II reactions in TRAIL-induced apoptosis -- results from dose-response studies.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210134

21 January 2018

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and TNF-alpha promote the NF-kappaB-dependent maturation of normal and leukemic myeloid cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210134

21 January 2018

Apoptosis and melanoma chemoresistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210134

21 January 2018

Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210134

21 January 2018

Multidomain Bcl-2 homolog Bax but not Bak mediates synergistic induction of apoptosis by TRAIL and 5-FU through the mitochondrial apoptosis pathway

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210134

21 January 2018

Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210134

21 January 2018

TRAIL and apoptosis induction by TNF-family death receptors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210134

21 January 2018

IFNgamma sensitization to TRAIL-induced apoptosis in human thyroid carcinoma cells by upregulating Bak expression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210134

21 January 2018

TRAIL sensitizes for ionizing irradiation-induced apoptosis through an entirely Bax-dependent mitochondrial cell death pathway

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210134

21 January 2018

Mechanisms of resistance to TRAIL-induced apoptosis in cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210134

21 January 2018

Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210134

21 January 2018

Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210134

21 January 2018

Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210134

21 January 2018

IFN-beta pretreatment sensitizes human melanoma cells to TRAIL/Apo2 ligand-induced apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210134

7 January 2021

based on heuristic

inferred from DOI database lookup

Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210134

7 January 2021

based on heuristic

inferred from DOI database lookup

PI-3K/Akt and NF-?B/I?B? pathways are activated in Jurkat T cells in response to TRAIL treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210134

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.ONC.1210134

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40198109&oldid=2203489217"